Waldencast Agrees to Sell Obagi Medical to Bridgepoint for $460M

Waldencast (NASDAQ: WALD) has agreed to sell its Obagi Medical business to private equity firm Bridgepoint for $460 million. The transaction will see Waldencast founders Michel Brousset and Hind Sebti transition from the company to lead Obagi in partnership with Bridgepoint.

By Amy Thielen, SA News Editor · Seeking Alpha · June 1, 2026, 18:45 UTC

Waldencast Agrees to Sell Obagi Medical to Bridgepoint for $460M

Topics: corporate transactions leadership transition

Read the full article at Seeking Alpha

More World news

San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC